The RELIEF ureteral stent is the first FDA-cleared stent for vesicoureteral reflux prevention in the US. The stent's design minimizes bladder spasms and reflux, improving patient comfort compared to ...

Results of subgroup analyses of the phase 3 CREST trial (NCT04165317) evaluating sasanlimab plus BCG compared with BCG alone in patients with high-risk non–muscle invasive bladder cancer (NMIBC) found ...

First-line nivolumab (Opdivo) plus ipilimumab (Yervoy) continued to show improved survival and durable response benefits vs sunitinib (Sutent) in patients with previously untreated advanced renal cell ...

In this interview, Mark C. Markowski, MD, PhD, discusses bipolar androgen therapy (BAT), including its advantages and disadvantages, trials that have evaluated the treatment, and what some next steps ...

Low-intensity extracorporeal shock wave therapy is a safe treatment for men with erectile dysfunction and might work to improve, or even cure, ED in some patients. But there remain important ...

MD, professor of urology and chief of andrology at Tulane University School of Medicine, in New Orleans, Louisiana. “About 20 years ago, when I gave a course at the American Urological Association ...

We identify a statistically higher odds of urethral stricture, genital numbness, and saddle sores (OR: 9.8, p<.001) in cyclists compared to swimmers/runners.Several other large studies corroborate ...

Specifically, the bill cuts funding for CDMRP from $1.509 billion in FY2024 to $650 million in FY2025. Prostate and kidney cancer research is currently funded at $110 million and $50 million, ...

First, CPT convention is specific in its recommendations for selecting a CPT code: "Select the CPT code of the procedure or service that accurately identifies the procedure or service performed. Do ...

The FDA’s Oncologic Drugs Advisory Committee (ODAC) voted in a unanimous 0-8 decision that the TALAPRO-2 data on talazoparib (Talzenna) in combination with enzalutamide (Xtandi) is not sufficient to ...

Key Takeaways. Prostate cancer is the most common urologic cancer, with PSA screening reducing mortality by up to 20% in men aged 55–69. Bladder cancer incidence is stable, with early detection ...

The panel discusses how fusion-guided biopsy can inform patient eligibility for focal therapy in prostate cancer.